NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
ATROPINE SULFATE (atropine sulfate) by Bausch + Lomb is muscarine-like actions of acetylcholine and is therefore classified as an anti-muscarinic agent. Approved for myopia. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Atropine Sulfate is an antimuscarinic ophthalmic solution approved for myopia treatment that blocks muscarinic acetylcholine receptors in the eye. It induces mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation) by inhibiting the pupillary sphincter and ciliary muscles. The drug is indicated for myopia management in pediatric and adult populations.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30); teams are likely focused on market penetration and share defense rather than growth expansion.
Mechanism of Action
muscarine-like actions of acetylcholine and is therefore classified as an anti-muscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does…
Indications (1)
Clinical Trials (3)
A Study of Atropine Sulfate in Healthy Chinese Volunteers
Started May 2023
30 enrolled
Pharmacokinetics
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Started May 2022
526 enrolled
Myopia
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Started Mar 2022
777 enrolled
Myopia
Worked on ATROPINE SULFATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.